Editorial Comment on “Efficacy and safety of dose‐dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle‐invasive bladder cancer”-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Editorial Comment on “Efficacy and safety of dose‐dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle‐invasive bladder cancer”

Published:2024-07-16 Issue: Volume: Page:
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J of Urology

Author:

Urabe Fumihiko¹^ORCID,Suzuki Hirotaka¹,Iwatani Kosuke¹²,Kimura Takahiro¹^ORCID

Affiliation:

1. Department of Urology The Jikei University School of Medicine Tokyo Japan

2. Department of Urology Jikei University Kashiwa Hospital Chiba Japan

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.15537

Reference4 articles.

1. Efficacy and safety of dose‐dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle‐invasive bladder cancer

2. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study

3. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

4. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP